- Home
- FUSB vs BCAB Comparison
FUSB vs BCAB Comparison
Compare FUSB & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- BCAB
- Stock Information
- Founded
- FUSB 1952
- BCAB 2007
- Country
- FUSB United States
- BCAB United States
- Employees
- FUSB N/A
- BCAB N/A
- Industry
- FUSB Major Banks
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- FUSB Finance
- BCAB Health Care
- Exchange
- FUSB Nasdaq
- BCAB Nasdaq
- Market Cap
- FUSB 65.8M
- BCAB 77.8M
- IPO Year
- FUSB N/A
- BCAB 2020
- Fundamental
- Price
- FUSB $13.75
- BCAB $0.69
- Analyst Decision
- FUSB
- BCAB Buy
- Analyst Count
- FUSB 0
- BCAB 2
- Target Price
- FUSB N/A
- BCAB $5.00
- AVG Volume (30 Days)
- FUSB 5.3K
- BCAB 895.9K
- Earning Date
- FUSB 01-23-2025
- BCAB 11-07-2024
- Dividend Yield
- FUSB 1.60%
- BCAB N/A
- EPS Growth
- FUSB 5.90
- BCAB N/A
- EPS
- FUSB 1.40
- BCAB N/A
- Revenue
- FUSB $40,310,000.00
- BCAB $11,000,000.00
- Revenue This Year
- FUSB N/A
- BCAB N/A
- Revenue Next Year
- FUSB N/A
- BCAB N/A
- P/E Ratio
- FUSB $9.82
- BCAB N/A
- Revenue Growth
- FUSB 0.79
- BCAB N/A
- 52 Week Low
- FUSB $8.66
- BCAB $0.67
- 52 Week High
- FUSB $14.30
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- FUSB 58.79
- BCAB 19.59
- Support Level
- FUSB $13.17
- BCAB $1.17
- Resistance Level
- FUSB $13.97
- BCAB $1.72
- Average True Range (ATR)
- FUSB 0.43
- BCAB 0.13
- MACD
- FUSB -0.07
- BCAB -0.06
- Stochastic Oscillator
- FUSB 51.33
- BCAB 2.12
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals and other individuals.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.